Abstract
Letter to the Editor in response to the article “Effect of luseogliflozin on liver fibrosis differs depending on alcohol consumption in patients with type 2 diabetes” highlighted the favorable changes in FIB‐4, HbAlc, weight loss, and serum albumin concentrations in drinkers and non‐drinkers with type‐2 diabetes and liver fibrosis. This retrospective study not only covered the facts respective to a topic but the depth and diversity of the study beamed so many perspectives which enhanced our concepts. Still, there is always a margin of uncertainties and addressing those limitations will enhance the validity of further studies.